Transdermally applied iloprost (ZK36-374) decreases whole blood platelet aggregation in normal volunteers.
D000279:Administration, Cutaneous; D004305:Dose-Response Relationship, Drug; D011464:Epoprostenol / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D016285:Iloprost; D007700:Kinetics; D010974:Platelet Aggregation / Q000187:drug effects*; D012016:Reference Values
D011464:Epoprostenol; D016285:Iloprost